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ABSTRACT
Although iron and zinc deficiencies are known to occur together and also appear to be high in Ghana, 
a few supplementation studies addressed this concurrently in pregnancy. In a double-blind, randomized 
controlled trial, 600 pregnant women in Ghana were randomly assigned to receive either a combined sup-
plement of 40 mg of zinc as zinc gluconate and 40 mg of iron as ferrous sulphate or 40 mg of elemental iron 
as ferrous sulphate. Overall, there was no detectable difference in the mean birthweight between the study 
groups, although the effect of iron-zinc supplementation on the mean birthweight was masked by a strong 
interaction between the type of supplement and the iron status of participants [F (1,179)=5.614, p=0.019]. 
Prenatal iron-zinc supplementation was effective in increasing the mean birthweight among anaemic and 
iron-deficient women but not among women with elevated iron stores in early pregnancy.
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INTRODUCTION
Analysis of birthweight data collected from ma-
jor hospitals in the Upper West Region of Ghana 
showed that the incidence of low birthweight (LBW) 
ranged from 15.0% to 29.1% (1). Birthweight has a 
significant influence on the growth and develop-
ment of a child  (2-5). Furthermore, several studies 
have identified LBW as an important risk factor for 
neonatal and infant mortality and impaired post-
natal growth (6-8). Unfortunately, LBW continues 
to affect a large proportion of infants, especially in 
developing countries, and is associated with high 
prevalence of chronic child undernutrition in these 
countries (9). This is a major challenge to the attain-
ment of Millennium Development Goals (MDGs), 
because adequate nutrition is critical to achieving 
the MDGs, especially goal four which aims at re-
ducing by two-thirds of the mortality rate among 
children aged less than five years by 2015 (10). 
Malaria and maternal anaemia continue to be sig-
nificant public-health problems in pregnancy, es-
pecially in developing countries (11,12). To reduce 
these problems in Ghana, pregnant women who at-
tend antenatal care services are given sulphadoxine 
pyrimethamine as chemoprophylaxis for malaria 
together with iron and folic acid but without zinc 
supplements. However, proxy indicators, which re-
flect zinc deficiencies strongly, suggest that the risk 
of zinc deficiency in Ghana may be high. Ghana is 
classified to be in the medium risk category in terms 
of zinc deficiency based on the prevalence of stunt-
ing (25.9%) and the estimated proportion of the 
population at risk of inadequate zinc intake (21.0%) 
by the International Zinc Nutrition Consultative 
Group Steering Committee (IZiNCG SC) (13). 
Zinc deficiency impairs the immune function and 
resistance to infections (14). Zinc-deficient preg-
nant women resident in malaria-endemic areas 
may, therefore, be more predisposed to reduced re-
sistance to malarial infections. Improved maternal 
zinc status through maternal supplementation may 
boost naturally-acquired immunity against malari-
al infection during pregnancy, thereby reducing its 
adverse consequences on foetal growth. Zinc-only 
supplementation against malaria in pregnancy 
may not be feasible since iron is already given rou-Saaka M et al. Prenatal zinc supplementation
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tinely to women who attend antenatal care services 
in most developing countries. Furthermore, the 
absence of evidence regarding the effectiveness of 
zinc-alone supplementation could be as a result of 
methodological and analytical flaws, or that some 
other unidentified limiting factors need to be ad-
dressed concurrently. In particular, although the 
inhibitory nature of iron and zinc in aqueous solu-
tions has been studied, the effect of maternal iron 
status on the supplementation of these nutrients is 
unclear. Furthermore, although empirical evidence 
suggests that iron and zinc deficiencies often occur 
together (15,16) and may impact on pregnancy 
outcomes, a few supplementation studies have ad-
dressed this concurrently in pregnancy (17). Con-
sequently, a combined effect of iron and zinc on 
birthweight merits further investigation.
Hypotheses
Prenatal zinc supplementation, in combination 
with a malaria prophylaxis, iron and folic acid in-
tervention package in a zinc-deficient and malaria-
endemic population, will increase the mean birth-
weight.
The secondary hypothesis was prenatal iron-zinc 
supplementation as an adjunct to chemoprophy-
laxis with sulphadoxine pyrimethamine will (a) in-
crease plasma zinc and iron concentrations, (b) in-
crease length of gestation, and (c) reduce incidence 
of LBW, intrauterine growth restriction (IUGR), and 
preterm delivery.
MATERIALS AND METHODS
Study design 
A prospective double-blind, randomized controlled 
trial was conducted in the Upper West Region of 
Ghana from September 2005 to November 2006. In 
this two-arm design, the iron-zinc group received 
a combined supplement of 40 mg of zinc as zinc 
gluconate and 40 mg of iron as ferrous sulphate. 
The control group received 40 mg of iron as ferrous 
sulphate. Both the groups also received chemopro-
phylaxis for malaria with sulphadoxine pyrimeth-
amine, and 400 µg of folic acid. The iron and zinc 
supplements were taken every other day from en-
rollment until delivery. The iron supplement given 
to participants in the control group was packaged 
exactly as the iron-zinc supplement.
Study participants
The study population comprised pregnant women 
who presented themselves for antenatal care (ANC) 
in the Wa Regional Hospital of the Upper West Re-
gion in Ghana. The inclusion criteria for the re-
cruitment of participants were all pregnant women 
who had earlier been assessed through ultrasono-
graphy and found to be no more than the 16-week 
period of gestation. Women were excluded if they 
were identified through interviews to be on any 
other form of zinc supplements at any dosage or 
were severely anaemic, i.e. haemoglobin (Hb) less 
than 7.0 g/dL.
Eligible women for the study gave a free and in-
formed consent before enrollment. The investiga-
tor explained, in the local dialect, the purpose and 
aims of the study to each potential participant. 
Women who agreed to participate in the study 
signed/thumb-printed the consent form and those 
who consented were given copies of the signed 
consent form. After enrollment, each participant 
was given a unique serial number, and this was re-
corded on her antenatal care card. 
Ethical clearance for the study was approved by the 
Edith Cowan University (ref. 04-276) and Ghana 
Health Service Ethical Review Committee (ref. 
GHS-ERC-3). 
Randomization
Participants were randomly assigned to one of 
the two study groups. An independent statistician 
generated the allocation schedule/sequence using 
computer-generated random numbers using the 
Excel software. After obtaining informed consent 
for enrollment, the midwife assigned participants 
in blocks of hundreds until the required sample 
size was met. There was no stratification during the 
randomization.
Concealment of random allocation sequence 
The assignment of participants to study conditions 
was administered at the study centre. The treat-
ment allocations generated were put in opaque en-
velopes and serially numbered. Each envelope con-
tained a card on which the specific treatment was 
indicated. To safeguard the allocation schedule/se-
quence, envelopes were opened sequentially and 
only after the participant’s name and other details 
were written on the envelope. The statistician who 
generated the allocation schedule kept the sched-
ule that contained the random allocations until the 
collection of data was completed. 
Blinding
The iron-zinc and iron-only supplements were pre-
coded and supplied by the Nutricaps Pharmaceuti-
cal Company, USA. The supplements (in the form Saaka M et al. Prenatal zinc supplementation
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of capsules) were of the same shape, colour, and 
taste. 
Administration of supplements and 
monitoring of compliance 
Each enrolled participant was instructed how to 
take the supplements, i.e. dosage and frequency. 
Participants were advised to take the supplements 
at least two hours before or after meals, and this 
translated practically to taking the supplements 
at night, just before going to bed, i.e. in the post- 
absorptive state. Each participant was supplied with 
enough supplements to last for two months at a 
time. Participants visited the hospital for antenatal 
care every four weeks. On these visits, they brought 
along the remainder of supplements supplied to 
them to monitor compliance by the research staff. 
Compliance/adherence  was  monitored  by  inter-
viewing the participants after having being en-
rolled for four weeks. A structured questionnaire 
was administered at home to check the frequency 
and dosage of intake of the supplement. The degree 
of compliance was measured in terms of the total 
number of capsules taken during the trial period. 
The fundamental elements that underlined full 
compliance included taking the correct dosage and 
frequency at the appropriate time, i.e. one capsule 
every other day in the post-absorptive stage.
Data collection
The blood samples analyzed for zinc were collected 
and plasma separated, stored at-34  0C until these 
were transported for analysis at the Ghana Nuclear 
Research Institute in November 2006. On the first 
antenatal care visit and at 34-36 weeks of gestation, 
a trained laboratory technologist collected fasting 
(more than 8 hours) venous blood samples (5 mL) 
from all the study participants. All fasting blood 
samples for analysis of plasma zinc were collected 
in the morning before 11.00 am to avoid diurnal 
variation in plasma zinc during the day. The fasting 
blood sugar level for each subject was also tested 
to make sure of the fasting state of the participant. 
The blood was collected into trace mineral-free 
EDTA bottles and refrigerated immediately until 
the plasma separated. Blood serum which was ana-
lyzed for ferritin was, however, separated from the 
cellular blood components using trace element-free 
techniques. Samples were stored, frozen at -34 0C 
and later transported by road for analysis.
The primary outcome variable was birthweight. The 
secondary end-points included, Hb, serum ferritin, 
plasma zinc concentrations, and length of gesta-
tion. Serum ferritin data were available for a sub-
sample of 213 women at recruitment, 173 of these 
were repeated at 34-36 weeks gestation because of 
the inability to assess them at the scheduled time. 
Data for the assessment of zinc status were available 
for a subgroup of 100 women at recruitment and 
repeated for 86 of them at 34-36 weeks of gestation. 
Malarial infection was also assessed at recruitment 
and in late pregnancy. Only participants who had 
a complete set of data were finally included in the 
analysis.
The dependent variables, therefore, included the 
following: (a) mean birthweight, (b) mean and 
changes in serum ferritin concentration, (c) mean 
and percentage changes in plasma zinc concentra-
tion, (c) length of gestation, and (d) incidence of 
LBW, IUGR, and preterm delivery.
Maternal height was measured on the first visit of 
the participant to the antenatal care clinic. Height 
was measured to the nearest 0.1 cm using a stadio-
meter. The Seca 767 digital adult scale was used 
for weighing the participants to the nearest 0.05 
kg at recruitment, 28 weeks of gestation, and 34-
36 weeks of gestation. Body mass index (BMI) was 
calculated automatically using the Seca 767 digital 
adult scale. Height of each participant in centime-
tre was entered into the scale with the BMI func-
tion made operational.
The blood pressure of the participants was mea-
sured at recruitment, 28 and 36 weeks of gestation 
by trained midwives, following standard proce-
dures.
A trained gynaecologist assessed gestational age 
at recruitment of participants on their first visit 
to the antenatal care clinic. In view of recall bias 
associated with the last menstrual period (LMP) 
approach, gestational age of the newborn was as-
sessed using biometric measurements of the foetus, 
i.e. ultrasound scanning. This assessment was done 
early in pregnancy (16-18 weeks). The dates for the 
assessment of gestational age at recruitment and at 
delivery were all recorded in a pre-designed data-
collection form. The length of gestation was sub-
sequently calculated in completed weeks from the 
recorded data.
Babies delivered in the hospital were weighed na-
ked within three hours of delivery using accurate 
and sensitive baby scales (Seca 334, Germany). The 
trained midwives recorded birthweight to the near-
est 1.0 g. The newborns were classified using the 
California Foetal Reference Curves recommended 
by the World Health Organization (WHO) (18).Saaka M et al. Prenatal zinc supplementation
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Fasting blood samples were collected at baseline and 
at 34-36 weeks of gestation from the participants to 
measure haemoglobin, serum ferritin, and plasma 
zinc. Concentration of haemoglobin was measured 
by the cyanmethemoglobin method (19,20). Serum 
ferritin was measured using a microparticle enzyme 
immunoassay on the Abbott AxSym chemistry an-
alyzer (Abbott Laboratories, Abbott Park, Illinois, 
USA). (21). Flame atomic absorption  spectropho-
tometry (AAS) (Varian Model AA 200, South Africa) 
was used for quantifying plasma zinc following a 
standardized procedure (22). 
Two hospital laboratory technologists diagnosed 
peripheral blood parasitaemia through microscopic 
examination of thin and thick blood smears. Ma-
laria parasite and leukocytes counts were made on 
the same microscopic fields, and a minimum of 
200 leucocytes was counted in each blood sample. 
Blood-films were classified as negative if no asexual 
form of Plasmodium falciparum was detected under 
100x magnifications.
Status of HIV was determined by the rapid test for 
HIV-1 and 2 and Determine HIV½ (23). Sociodemo-
graphic and other information were collected in the 
third trimester using a structured questionnaire.
Calculation of sample size and sampling 
procedure
With two-sided hypothesis testing, the probabili-
ty of committing type I (false-positive) and type 
II (false-negative) errors was set at alpha=0.05 and 
beta=0.2 respectively. The estimated effect size was 
150 g. The natural variability (standard deviation) of 
the mean birthweight calculated from birthweight 
data collected from the study population prior to 
this study was 580 g. So, the required sample size 
(n) for each study group was calculated following a 
standard formula (24,25).
The required sample size large enough to detect a 
reliable smallest difference in the primary outcome 
was 470. Allowing for a 15% loss to follow-up and 
about 2% multiple births, i.e. 41 women, the esti-
mated sample size per group was 300. The overall 
sample was adjusted to 600 pregnant women.
Data management and analyses
Data were collected on pre-designed forms and 
registers and edited in the field for completeness 
and consistency before entry into a computer for 
analysis. The data were coded for statistical analysis 
using the SPSS software for Windows (version 14.0) 
(SPSS Inc, Chicago, IL, USA).
Before formal statistical tests were applied, the da-
taset was explored to verify whether conditions 
for parametric tests were met, e.g. normality and 
homogeneity of variance. Data that failed the nor-
mality test were log-transformed before a paramet-
ric test could be used. Effect modification and con-
founding were identified and adjusted for during 
data analysis through stratified and/or multivariate 
analyses. An interaction analysis was used for in-
vestigating subgroup effects between treatment and 
maternal iron status, and the treatment effect was 
presented by substrata. The rationale behind this 
lies with the fact that whenever interaction is pres-
ent, strata-specific estimates instead of summary 
measures of association are to be reported (26). The 
investigators had suspected this kind of interaction 
right from the design stage because several studies 
reported high maternal iron stores and especially 
when supplemented with iron during pregnancy 
resulted in adverse pregnancy outcomes (27-30).
As the dataset included some repeated measures 
(for example, density of parasites, serum ferritin, 
and zinc), analysis of covariance (ANCOVA) was 
used for determining the post-test differences be-
tween the treatment groups. ANCOVA was also 
used for adjusting group means because some out-
comes, e.g. birthweight, were influenced by multi-
ple prognostic factors. Multiple regression analysis 
was also used for determining the minimum set of 
variables that accounted for the proportion of vari-
ance of the primary outcome measure, i.e. mean 
birthweight. 
Multivariate logistic modelling technique was per-
formed to determine the set of risk factors that pre-
dicted the mean birthweight and the risk of LBW 
(< 2,500), IUGR (birthweight below the 10th percen-
tile), and premature delivery (<37 weeks). Statistical 
difference was considered significant if the p value 
was <0.05, and 95% confidence intervals (CIs) were 
calculated for all main outcome measures.
RESULTS
Sample characteristics
The mean age of the study participants at recruit-
ment was 27±5.4 years with a range of 16-44 years. 
The baseline maternal characteristics, including 
nutritional indicators, to compare the study groups 
are presented in Table 1. The mean gestational age 
at recruitment was 13.0±3.0 completed weeks. The 
study groups did not differ significantly in terms 
of their baseline characteristics, except for age 
where the iron-zinc group had older participants [F 
(1,598)=4.864, p=0.028)]  (Table 1). Saaka M et al. Prenatal zinc supplementation
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Follow-up and compliance with supplements
The number of participants recruited, enrolled, and 
loss-to-follow-up is shown in the Figure. 
The total loss-to-follow-up rate was 9.5%; this was 
less than 10.0% and was, therefore, not a threat to 
the validity and power of the study. In total, 9.0% 
(n=27) of the participants (n=299) were lost-to-fol-
low-up in the zinc-supplemented group compared 
to 9.9% (n=30) of the participants (n=301) in the 
control group. The minimum total sample size 
required to detect the 150 g mean birthweight dif-
ference at 80% power was calculated to be 470, and 
543 participants completed the study.
Pregnancy loss, i.e. miscarriages, spontaneous abor-
tions, and stillbirths, accounted for 45.6% (n=26) 
of the participants who were lost-to-follow-up, and 
1.3% (n=7) of the total deliveries (n=550) were mul-
tiple births. In addition, 4.0% (n=24) of the total 
number of randomized participants were lost at dif-
Table 1. Baseline characteristics and comparability of treatment groups
Characteristics
Control group 
( n=301)
Iron-zinc group 
(n=299)
Mean SD Mean SD
Maternal age (years) 26.4 5.0 27.4 5.6
Geometric mean density of malaria parasite (parasites/
µL blood)
 
464.0
 
3.0
 
342.0
 
4.0
Geometric mean concentration of plasma zinc (µg/dL) 26.4 2.5 26.2 2.5
Hb concentrations (g/dL) 11.3 1.5 11.2 1.4
Geometric mean concentration of serum ferritin (µg/L) 33.2 2.4 34.8 2.3
Maternal height (cm) 159.1 5.6 159.2 6.0
Maternal weight (kg) 63.2 12.1 63.1 10.9
Body mass index  (kg/m2) 25.0 4.5 25.0 4.0
Gestational age at recruitment (weeks) 13.7 2.9 13.8 2.9
Diastolic blood pressure (mm Hg) 59.0 10.0 59.0 10.0
Systolic blood pressure (mm Hg) 103.5 12.7 102 13.2
Parity 1.41 1.55 1.64 1.89
SD=Standard deviation
Fig. A ﬂow diagram showing the number of participants recruited, randomized, and lost-to-follow-up
Randomized (n=600) 
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Q 
Allocated to test treatment (n=299)
Received allocated treatment (n=299)
Did not receive allocated test treatment (n=0)
Lost-to-follow-up (n=27)  
Discontinued test treatment (n=0) 
Exclusion due to severe 
anaemia (n=10) 
Eligible participants approached (n=762) 
Lost-to-follow-up (n=30)  
Discontinued control 
Allocated to control treatment (n=301)  
Received allocated treatment (n=301)  
Did not receive control treatment (n=0) 
Analyzed (n=272)
Excluded from analysis (n=27)   
Analyzed (n=271)
Excluded from analysis (n=30)   Saaka M et al. Prenatal zinc supplementation
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ferent stages of the trial as they travelled out of the 
study area and could not be traced.
There were no differences in the compliance levels 
between the study groups. Full compliance/adher-
ence in the study was generally high and was mea-
sured in terms of dosage, time, and frequency of 
taking the supplements. Partial compliance meant 
that a participant did not take her supplement at 
the prescribed time, dosage, or frequency. The de-
gree of compliance was measured in terms of the to-
tal number of capsules taken during the trial period.
Of the participants enrolled, 91.7% (n=550) de-
livered, and seven of the women delivered twins. 
There were, therefore, 543 singleton livebirths; 
49.8% (n=269) were males, and 50.2% (n=271) were 
females. Of the 543 singleton livebirths, 91.5% 
(n=497) were by spontaneous vaginal delivery 
(SVD) and 8.5% (n=46) by caesarean section.
Effect of iron-zinc supplementation on 
pregnancy outcomes
Overall, there was no detectable difference in the 
mean birthweight between the study groups. The 
adjusted mean birthweight in the iron-zinc group 
was 3,105±490 g and in the control group was 
3,120±486 g. However, adjusted for gestational 
weight gain between week 28 and week 36, diastolic 
pressure at 34-36 weeks of gestation, gender of 
baby, IUGR, preterm delivery, length of gestation, 
maternal weight, and gravidity through ANCOVA 
analysis, an interaction between maternal iron sta-
tus at recruitment and treatment type manifested 
[F (1,179)=5.614, p=0.019]. Consequently, adjusted 
for diastolic pressure at 34-36 weeks of gestation, 
gender of baby, gestational weight gain between 28 
and 36 weeks of gestation, IUGR, length of gesta-
tion, preterm delivery, and BMI, the adjusted mean 
birthweight of babies born to women in the iron-
zinc group was 131 g higher than the adjusted 
mean birthweight of babies born to women who 
received the standard treatment [(3,223 g vs 3,092 
g), F (1,121)=4.210, p=0.042] among anaemic 
women (Hb < 9.0 g/dL) and/or iron-deficient wom-
en (serum ferritin <35 µg/L). Among women who 
were iron-sufficient (serum ferritin ≥35 µg/L) at re-
cruitment, the adjusted mean birthweight in the 
iron-zinc supplemented group was not different 
from that of the control group [(3,032 g vs 3,053 g), 
F (1, 94)=0.762, p=0.762]. 
There was no significant difference in the mean 
length of gestation between the study groups even 
after adjusting for the main determinants. The 
mean length of gestation in the iron-zinc and the 
control group were 37.1±1.8 and 37.2±1.7 respec-
tively [F (1,541)=0.144, p=0.704]. The other ad-
verse pregnancy outcomes and the risk of the event 
occurring in the iron-zinc compared to the stan-
dard treatment group are shown in Table 2.
Determinants of birthweight
Determinants of birthweight in the whole sample 
and among iron-deficient and iron-sufficient wom-
en are shown separately in Table 3, 4, and 5 respec-
tively. Variables entered in the regression analysis 
included malarial infection in early pregnancy, 
maternal age, type of treatment, use of sulphadox-
ine pyremethamine, and gravidity but these were 
excluded from the model for the whole sample 
because of their weak association with birthweight. 
This set of predictors in the separate models for 
birthweight explained 43.6% and 54.9% of varia-
tion in birthweight among iron-deficient and iron-
sufficient women respectively. Malarial infection 
in early pregnancy was an important determinant 
of birthweight only among iron-sufficient women. 
Preterm delivery was not an important determi-
nant of birthweight among iron-sufficient women 
but it was important among iron-deficient wom-
en. Type of supplement was an important determi-
nant of birthweight among iron-deficient but not 
among iron-sufficient women. Among iron-
Table 2.  Effect of iron-zinc supplementation on selected adverse pregnancy outcomes
Outcome
Iron-zinc group 
 (n= 272)
Control group 
 (n= 271) Relative risk 95% CI
No          % No          %
Total LBW  26          9.6 21          7.7 1.23 0.71, 2.14
Term LBW  12          5.2 8            3.4 2.84 0.69, 11.75
Preterm delivery with LBW  14          35.0  13          33.3 1.16 0.37, 3.62
Total IUGR  14          5.1 18          6.6  0.78 0.39, 1.53
Preterm delivery 40          14.7 39         14.4 1.02  0.68, 1.54
CI=Confidence interval; IUGR=Intrauterine growth restriction; LBW=Low birthweightSaaka M et al. Prenatal zinc supplementation
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Table 3. Determinants of birthweight (whole sample)
Determinant
Unstandardized 
coefficients
Standardized 
coefficients 
beta
T p value 95% CI for ß
ß SE
(Constant) -0.923 0.529   -1.745 0.082 -1.963, 0.116
-0.014, 0.001 Maternal age of participant -0.007 0.004 -0.078 -2.009 0.045
Diastolic pressure at 36 weeks 
gestation
-0.003 0.002 -0.070 -2.115 0.035 -0.006, 0.001 
-0.169, -0.047 Gender of baby -0.108 0.031 -0.111 -3.471 0.001
Intrauterine growth restriction  -0.816 0.068 -0.395 -11.981 0.001 -0.950, -0.683
Length of gestation 0.103 0.014 0.361 7.478 0.001 0.076, 0.129
0.058, 0.208 Proxy socioeconomic class 0.133 0.038 0.114 3.500 0.001
Nulliparity 0.192 0.040 0.188 4.780 0.001 0.113, 0.271
Alcohol drinking status 0.136 0.048 0.090 2.833 0.005 0.042, 0.231
Preterm delivery -0.191 0.066 -0.138 -2.883 0.004 -0.320, -0.061
Maternal weight  0.007 0.001 0.158 4.630 0.001 0.004, 0.010
SE=Standard error
Table 4. Determinants of birthweight among iron-deficient women
Variable
Unstandardized 
coefficients Standardized 
coefficients beta
T p value
95% confi-
dence inter-
val for ß ß SE
(Constant) 0.361 1.405   0.257 0.798 -2.427, 3.149
Supplement type -0.134 0.071 -0.141 -1.888 0.062 -0.276, 0.007
Maternal weight  0.006 0.003 0.181 2.290 0.024 0.001, 0.012
Diastolic pressure at 36 
weeks gestation
 
-0.005
 
0.004
 
-0.115
 
-1.420
 
0.159
 
-0.012, 0.002
Gender of baby -0.139 0.073 -0.146 -1.920 0.058 -0.283, 0.005
IUGR -0.978 0.160 -0.473 -6.121 0.001 -1.295, -0.661
Length of gestation 0.085 0.037 0.270 2.294 0.024 0.011, 0.158
Preterm delivery -0.414 0.162 -0.294 -2.561 0.012 -0.735, -0.093
IUGR=Intrauterine growth restriction; SE=Standard error                              
Table 5. Determinants of birthweight among iron-sufficient women
Variable 
Unstandardized 
coefficients
Standardized 
coefficients T p value
95% confidence 
interval for ß
  ß SE beta
(Constant) -3.543 0.826 -4.290   0.001 -5.182, -1.905
Intrauterine growth 
restriction 
 
-0.857
 
0.111
 
-0.527
 
-7.691
 
0.001
 
-1.078, -0.636
Gestational age in 
weeks at delivery
 
0.192
 
0.021
 
0.613
 
8.934
 
0.001
 
0.149, 0.234
Malarial infection at 
recruitment
 
-0.268
 
0.093
 
-0.191
 
-2.867
 
0.005
 
-0.453, -0.083
SE=Standard error                              
deficient women, women who received standard 
treatment, i.e. iron-only, gave birth to babies 
whose mean birthweight was 0.141 standard 
units lower than women who received the iron-
zinc supplement.
Effect of iron-zinc supplementation on 
maternal zinc and iron status
The geometric mean concentrations of plasma 
zinc at recruitment and at 34-36 weeks of gestation Saaka M et al. Prenatal zinc supplementation
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were 26.3±2.5 µg/dL (95% confidence interval [CI] 
24.1-28.6) and 40.1±2.7 µg/dL (95% CI 32.5-49.4) 
respectively. Treatment effect was different depend-
ing on the maternal zinc status at recruitment in 
the subgroup of the participants for whom plasma 
zinc was assessed. Adjusted for amount of supple-
ment consumed, a strong interaction between the 
maternal zinc status and the type of supplement 
modified the treatment effect on geometric plasma 
zinc at 34-36 weeks [F (1,81)=4.765, p=0.032]. Con-
sequently, among women who had low concen-
trations of plasma zinc at baseline, the adjusted 
geometric mean plasma zinc in the iron-zinc group 
was higher than that in the control group, al-
though not significant [(41.2 µg/dL vs 31.2 µg/dL), 
F (1,56)=1.103, p=0.298]. The geometric mean con-
centration of plasma zinc was adjusted for IUGR, 
z-score plasma zinc concentrations at recruitment, 
and maternal age. Among women who were not 
zinc-deficient (plasma zinc ≥60 µg/dL) at recruit-
ment, the adjusted geometric mean concentrations 
of plasma zinc at 34-36 weeks of gestation tended 
to be higher in the iron-zinc group compared to 
the control group [(69.8 µg/dL vs 44.4 µg/dL), F 
(1,22)=2.236, p=0.149]. Women with low levels of 
plasma zinc (<60.0 µg/dL) at recruitment also had 
significantly higher Hb compared to women who 
had relatively higher plasma concentrations at re-
cruitment.
The adjusted geometric mean plasma zinc at 34-
36 weeks of gestation was higher among women 
who had normal concentrations of plasma zinc 
(≥60 µg/dL) compared to women who were zinc-
deficient in early pregnancy [(88.7 µg/dL vs 28.9 
µg/dL), F (1,82)=10.010, p=0.002)]. Geometric con-
centrations of plasma zinc were adjusted for IUGR 
and z-score plasma zinc concentrations at baseline, 
gender. 
Relationship of maternal plasma zinc with 
iron status parameters
The relationships between the maternal zinc sta-
tus and the iron status indicators were assessed 
in a subsample of the study participants. Women 
who had low levels of plasma zinc (<60.0 µg/dL) 
at recruitment had also significantly higher Hb but 
lower serum ferritin and iron concentrations com-
pared to women with normal values (≥60 µg/dL). 
Concentrations of plasma zinc in early pregnancy 
positively correlated with serum ferritin (r=0.137, 
p=0.069) and serum iron (r=0.261, p=0.001). Con-
centrations of plasma zinc correlated negatively 
with Hb (r=-0.165, p=0.001) in early pregnancy. 
DISCUSSION
The uniqueness of this study lies in the fact that, 
although previous supplementation studies involv-
ing zinc have included iron, these nutrients have 
not been administered as a single supplement as 
was done in this study. To minimize the possible 
absorptive  competitions  between  iron  and  zinc, 
they were administered in a 1:1 ratio and was taken 
every other day and not every day. 
Additionally, this study is different from other zinc 
trials in that, the interaction effect between supple-
ments administered and high maternal iron/Hb 
status was isolated making it clear that combined 
supplementation of iron and zinc is potentially 
beneficial among iron-deficient and/or anaemic 
but not iron-sufficient or non-anaemic women. 
This study recognized that failure to control for the 
numerous confounding factors on birthweight and 
the interaction effect between the maternal iron 
status and zinc may mask the efficacy of iron-zinc 
supplementation. Therefore, important prognostic 
variables, including malarial infection, were as-
sessed at recruitment and in late pregnancy.
Maternal iron status in early pregnancy interacted 
substantially with the combined iron-zinc supple-
ment on the mean birthweight, change in the mean 
plasma zinc, the mean Hb, and geometric mean 
concentrations of serum ferritin at 34-36 weeks of 
gestation. The presence of interaction implied that 
the efficacy of iron-zinc supplementation was dif-
ferent and dependent on the iron status at recruit-
ment. Generally, iron-zinc supplementation was 
effective among women who were anaemic and/or 
iron-deficient at recruitment.
Effect of iron-zinc supplementation on mean 
birthweight
Overall, there was no detectable difference in the 
mean birthweight between the study groups. Iron 
status indicators, i.e. serum ferritin and Hb, inter-
acted substantially with a combined iron and zinc 
supplement on the mean birthweight. The investi-
gators suspected that treatment effect of iron-zinc 
supplementation would be different for women 
with different iron stores because several studies 
have reported high maternal iron stores and, espe-
cially when supplemented with iron during preg-
nancy, resulted in adverse pregnancy outcomes 
(27-30). The presence of interactions implied ad-
justment for confounding was contra-indicated. 
Whenever interaction is present, strata-specific esti-
mates, instead of summary measures of association 
and effects, are to be reported (26). Saaka M et al. Prenatal zinc supplementation
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Efficacy of iron-zinc supplementation was higher 
among women who were iron-deficient. Zinc-only 
supplementation has not demonstrated any posi-
tive effect on pregnancy outcomes in some studies, 
and one may wonder why iron-zinc supplementa-
tion would result in a higher birthweight whereas 
zinc alone does not. One possible reason for the 
negative results in many studies may be due to the 
fact that most studies that investigated the effect 
of zinc-only supplementation on birthweight did 
not explore the interaction effect of maternal iron 
status on treatment effect. Failure to control the in-
teraction effect of maternal iron status may lead to 
a conclusion of no effect. For instance, the study 
by Caulfield and colleagues in Peru did not test 
for interaction/antagonism between the maternal 
iron status and the zinc supplements administered 
(31). Indeed, a failure to recognize and report inter-
action, if it exists, is a missed opportunity to note 
differences in outcomes, or associations, between 
subgroups in the study.
Other explanations for the high efficacy of com-
bined iron and zinc compared to iron-only sup-
plementation among iron-deficient women may 
be that absorption of iron would have improved 
through the reductive effect of zinc on infections, 
such as malaria which is reported to be endemic in 
the study area. Second, zinc promotes the forma-
tion of insulin-like growth factor-1 (IGF-1) which, 
together with erythropoietin, are required for hae-
matopoiesis (32,33). These processes are essential 
for normal foetal growth.
Another possible explanation for the improve-
ment in the mean birthweight among anaemic 
women who received iron-zinc supplementation 
may relate to an efficient supply of oxygen to the 
foetus. Oxygen is needed for the normal develop-
ment of the placenta and for the release of growth 
hormones from the placenta and that the size of 
the placenta has an inverse relationship to mater-
nal haemoglobin level (34). The synthesis of IGF-1 
has been reported to be facilitated by glucose (35), 
and its action is potentiated by the presence of zinc 
(36). Although maternal IGF-1 does not cross the 
placenta and, therefore, does not have a direct ef-
fect on foetal growth, it may facilitate exchange of 
nutrient and oxygen between the placenta and the 
foetus. 
The inability of iron-zinc supplementation to in-
crease the mean birthweight among the iron-suf-
ficient women in this study is not an isolated case. 
Several studies have earlier demonstrated poor 
pregnancy outcomes with high Hb (29,30), and it 
has been suggested that there may be underlying 
causes other than the high Hb that may be respon-
sible for this association (37). One possible reason 
why there was no treatment effect among the iron-
sufficient women may be increased blood viscos-
ity, resulting from iron-induced macrocytosis (38). 
An exponential or linear relationship between high 
Hb and blood viscosity is well-established (39). 
High Hb per se may not cause blood viscosity but 
it may serve as an indicator of high blood viscosity. 
A number of factors, including pre-eclampsia, are 
reported to limit expansion of plasma volume with 
the resultant high Hb concentrations (40). 
Similar studies carried out in Peru, Nepal, and Ban-
gladesh have reported no association between pre-
natal maternal zinc supplementation and mean 
birthweight (31,41,42). Evidence from this and 
the Peruvian and the Nepalese studies concluded, 
overall, that there was no effect of iron-zinc supple-
mentation on birthweight. Further analysis of data 
in this study, however, showed that the effect of 
iron-zinc supplementation was masked by a strong 
interaction between the type of supplement and 
the iron status of participants at recruitment. As-
sessing the efficacy of iron-zinc supplementation 
needs to take into consideration the iron status of 
participants at baseline. It is worth mentioning that 
when women with low concentrations of plasma 
zinc were selected during data analyses, there was 
still no demonstrable efficacy of iron-zinc supple-
mentation. This may be attributed to the fact that 
most women with low concentrations of plasma 
zinc also had high Hb concentrations. Given the 
obvious interaction between zinc supplement and 
maternal Hb level, the efficacy of iron-zinc supple-
mentation on birthweight among women with 
high Hb will naturally be reduced. 
The fact that marginal iron and zinc deficiencies 
co-existed in this study population presupposed 
correcting one deficiency without the other may 
not have made the desired impact on pregnancy 
outcomes. Furthermore, iron-zinc supplementation 
was effective in improving the mean birthweight 
among iron-deficient women. It may, therefore, be 
inferred that zinc deficiency was an important limi-
ting factor and, therefore, correction of iron defi-
ciency alone in this study population was unlikely 
to improve birthweight. As shown in several stud-
ies (43,44), iron-only supplementation is unlikely 
to increase birthweight. 
Combined iron and zinc may be an appropriate 
strategy for increasing the mean birthweight, es-
pecially among iron-deficient women. Improved Saaka M et al. Prenatal zinc supplementation
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zinc status is a potential factor which could have 
influenced foetal growth in the subgroup of iron-
zinc deficient women. Supplementation of zinc is 
reported to increase IGF-1 in Japanese pregnant 
women, which was positively associated with birth-
weight (r=0.404, p<0.05) (45). Zinc plays a central 
role in cellular growth and development during 
pregnancy through its influence on the growth 
hormone and the enzyme system that regulate cell 
division (46-49). The increased mean birthweight 
among iron-deficient women confirms some ear-
lier observations that women with serum ferritin of 
less than 35 µg/L during pregnancy is always asso-
ciated with a lack of iron in bone-marrow (50), and 
the possible association with zinc deficiency (51) 
may, therefore, better respond to iron-zinc supple-
mentation.
Effect of iron and zinc supplementation on 
LBW, IUGR, and preterm delivery
This study showed that iron-zinc supplementation 
tended to be protective of the risk of IUGR (relative 
risk [RR]=0.78; 95% CI: 0.39-1.53) but had no ef-
fect on preterm delivery. In the adjusted logistic 
regression model (enter method), iron-zinc supple-
mentation still remained weakly protective of IUGR 
(odds ratio [OR]=0.84, CI 0.40-1.78). The variables 
adjusted for were: gravidity, height, and diastolic 
pressure at 34-36 weeks of gestation. The associa-
tion was, however, not statistically significant at a 
5% significance level. 
Overall, iron-zinc supplementation was associ-
ated with an insignificant increased risk of LBW 
(RR=1.23; 95% CI 0.71-2.14). There was also no 
apparent effect of iron-zinc supplementation on 
preterm delivery in the study. The protective role 
of zinc supplementation on IUGR and preterm de-
livery has been inconsistent. As candidly submitted 
by de Onis et al (52), benefits from zinc supplemen-
tation can only be realized in zinc-deficient popula-
tions. While some studies have found low maternal 
plasma zinc to be a risk factor for preterm delivery 
(53), others did not (54,55). Some zinc-supplemen-
tation trials had a positive effect on preterm deliv-
ery (56-58). 
Effect of combined iron and zinc supplemen-
tation on maternal iron and zinc status
In view of the unreliability of concentrations 
of plasma zinc as an indicator of zinc nutriture, 
changes in the mean concentrations of plasma 
zinc, i.e. responsiveness, to iron-zinc supplemen-
tation may better reflect iron and zinc deficiency 
than any one-time measurement in a given popu-
lation. However, response to iron-zinc supplemen-
tation was also greatly influenced by some inter-
actions between the supplement administered and 
the maternal iron and zinc status. 
Anaemia at recruitment, which is a measure of iron 
status and also a reflection of end-stage iron defi-
ciency, interacted substantially with the treatment 
on a number of outcomes, including geometric 
mean concentrations of plasma zinc at 34-36 weeks 
of gestation, birthweight, mean change in Hb, and 
mean concentrations of serum ferritin in late preg-
nancy.  Generally,  iron-zinc  supplementation  was 
effective among women who were anaemic and/or 
iron-deficient at recruitment.
Selection of women for iron-zinc supplementa-
tion based on low concentrations of plasma zinc 
alone may also be inadequate because this group 
of women was found to have high Hb concentra-
tions. Women of concurrent marginal zinc defi-
ciency and high Hb may not respond adequately 
to iron-zinc supplementation because of the strong 
effect modification exerted by their iron status in 
early pregnancy on birthweight, plasma zinc, and 
Hb. Women with low plasma zinc and concurrent 
Hb less than 9.0 g/dL demonstrated the greatest po-
tential of benefiting maximally from iron-zinc sup-
plementation. The treatment effect on maternal 
zinc response was observed mainly among women 
with low Hb. 
A pertinent question one is tempted to ask is ‘was 
high Hb a cause for lack of efficacy with iron-zinc 
supplementation or is it an indicator of some un-
derlying cause’? High Hb may result from increased 
red cell mass as a compensatory response to inade-
quate oxygen supply to tissues or as a result of in-
adequate plasma volume expansion (39). Indeed, 
inadequate oxygen supply and poor plasma 
volume expansion have the potential of limiting 
foetal growth.
The prevalence of low concentrations of plasma 
zinc in the subsample was strikingly high and may 
be attributed to a number of factors. Aside poor-
quality diets, a number of factors, such as infec-
tions, not necessarily relating to nutritional zinc 
status, may have influenced plasma zinc levels. 
Low concentrations of plasma zinc during preg-
nancy may not necessarily reflect zinc deficiency as 
infections (59,60), haemodilution, and other meta-
bolic changes can contribute to low zinc levels (61). 
These factors, therefore, further complicate the di-
agnosis and interpretation of real zinc deficiency Saaka M et al. Prenatal zinc supplementation
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during pregnancy and in assessing the efficacy of 
iron-zinc supplementation.
Relationship between plasma zinc and iron 
status parameters
There were strong relationships between the mater-
nal zinc status and the iron status indicators, i.e. Hb 
and serum iron, in early pregnancy. Women with 
low levels of plasma zinc had also high concentra-
tions of Hb at recruitment. Of the 114 women who 
were iron-deficient at recruitment, 88.6% (101/114) 
also had low concentrations of zinc. There was, 
therefore, a strong association between maternal 
zinc and the iron status in  this study population; a 
relationship that has also been consistently shown 
in the United States (15,62). 
Women with low levels of (<60.0 µg/dL) plasma 
zinc at recruitment also had significantly higher Hb 
but lower serum ferritin and iron concentrations 
compared to women with normal values (≥60 µg/
dL). Although a negative relationship between plas-
ma zinc and Hb in early pregnancy was observed 
in this study, a study among pregnant Malawian 
women reported lack of correlation between serum 
zinc and Hb (63). 
What are the possible explanations for the nega-
tive association between Hb and plasma zinc 
levels in early pregnancy observed in this study?
One possible mechanism that may help explain 
the negative relationship between plasma zinc and 
Hb concentrations in this study is that low plasma 
zinc may be associated with inadequate expansion 
of plasma volume and, therefore, little haemodi-
lution effect and subsequent high Hb. Poor nutri-
tional profile in early pregnancy is positively asso-
ciated with reduced plasma volume (64,65), and it 
is possible that low concentrations of plasma zinc 
were partly reflective of the poor nutritional status 
of women. The high Hb may also be a reflection 
of inadequate plasma volume expansion, vis-à-vis 
increased red cell mass that had taken place.
Additionally, increased foetal erythropoiesis may 
result in reduced plasma zinc but stimulate mater-
nal erythropoiesis with a resultant increase in ma-
ternal Hb.
It is concluded that combined prenatal iron and zinc 
compared to iron-only supplementation was more 
effective in increasing the mean birthweight among 
iron-deficient women but not among women with 
elevated iron stores in early pregnancy. There was 
no discernible diference in the mean birthweight 
between the study groups among women who 
were iron-sufficient in early pregnancy.
Interaction reduces efficacy, and this must be re-
cognized and isolated in all future supplemen-
tation studies involving iron and zinc. Additionally, 
early detection of high levels of serum ferritin in 
pregnant women should alert health workers to 
critically examine such clients for a possibility of 
infections and/or reduce the dosage of prescribed 
iron supplements. The findings also bring to fore 
the need for adequate laboratory facilities for the 
routine diagnosis of serum ferritin levels in health 
institutions.
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